Fredrik Lehmann
Director/Board Member chez GUARD THERAPEUTICS INTERNATIONAL AB
Profil
Dr. Fredrik Lehmann is an Independent Director at Guard Therapeutics International AB, a Venture Partner at Industrifonden, an Independent Director at Sprint Bioscience AB, a Chairman at Synartro AB and a Chief Executive Officer & Director at OT Pharmaceuticals AB.
He is on the Board of Directors at Guard Therapeutics International AB, Sprint Bioscience AB, OT Pharmaceuticals AB, AnaCardio AB, Immuneed AB and OT Lehmann Holding AB.
Dr. Lehmann was previously employed as a CMC Director by Axelar AB, a Head-Research, Chemistry, Manufacturing & Control by Oncopeptides AB, a CEO by OnTarget Chemistry AB, a Chief Executive Officer by EpiEndo Pharmaceuticals ehf, and a General Manager by Recipharm OT Chemistry AB.
He also served on the board at Akinion Pharmaceuticals AB.
He received his graduate degree from the University of Uppsala, an MBA from Stockholm School of Economics and a doctorate degree from the University of Gothenburg.
Postes actifs de Fredrik Lehmann
| Sociétés | Poste | Début |
|---|---|---|
| SPRINT BIOSCIENCE AB | Director/Board Member | 01/01/2019 |
| GUARD THERAPEUTICS INTERNATIONAL AB | Director/Board Member | 01/12/2022 |
Industrifonden
 Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Private Equity Investor | 01/10/2022 |
Immuneed AB
 Immuneed AB Medical SpecialtiesHealth Technology Immuneed AB develops drugs. The firm offers as a contract research organization and provides specialized services for immunotoxicology and immunophenotyping. Its services include cytokine release assay, complement activation, cellular drug biodistribution, cell activation patterns, immune recall responses, viability analyses, blood status and mode-of-action studies. The company was founded by Sara Mangsbo, Erika Fletcher and Thomas Totterman in 2014 and is headquartered in Uppsala, Sweden. | Director/Board Member | - |
| OT Pharmaceuticals AB | Chief Executive Officer | - |
| Synartro AB | Chairman | - |
OT Lehmann Holding AB
 OT Lehmann Holding AB Investment Banks/BrokersFinance OT Lehmann Holding AB provides securities and property management services. The private company is based in Stockholm, Sweden. | Director/Board Member | - |
AnaCardio AB
 AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Director/Board Member | - |
Anciens postes connus de Fredrik Lehmann
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOPEPTIDES AB | Chief Tech/Sci/R&D Officer | 30/09/2022 |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Fredrik Lehmann
| Stockholm School of Economics | Masters Business Admin |
| University of Uppsala | Graduate Degree |
| University of Gothenburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| SPRINT BIOSCIENCE AB | Health Technology |
| GUARD THERAPEUTICS INTERNATIONAL AB | Health Technology |
| Entreprise privées | 11 |
|---|---|
Industrifonden
Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Finance |
Axelar AB
 Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
OnTarget Chemistry AB
 OnTarget Chemistry AB BiotechnologyHealth Technology Part of Recipharm AB, OnTarget Chemistry AB provides research services for medicinal synthesis and pharmaceutical products. The private company is based in Uppsala, Sweden. OnTarget Chemistry was acquired by Recipharm AB on June 15, 2015 for $1.85 million. | Health Technology |
Immuneed AB
Immuneed AB Medical SpecialtiesHealth Technology Immuneed AB develops drugs. The firm offers as a contract research organization and provides specialized services for immunotoxicology and immunophenotyping. Its services include cytokine release assay, complement activation, cellular drug biodistribution, cell activation patterns, immune recall responses, viability analyses, blood status and mode-of-action studies. The company was founded by Sara Mangsbo, Erika Fletcher and Thomas Totterman in 2014 and is headquartered in Uppsala, Sweden. | Health Technology |
OT Lehmann Holding AB
OT Lehmann Holding AB Investment Banks/BrokersFinance OT Lehmann Holding AB provides securities and property management services. The private company is based in Stockholm, Sweden. | Finance |
Recipharm OT Chemistry AB
 Recipharm OT Chemistry AB Pharmaceuticals: MajorHealth Technology Part of Recipharm AB, Recipharm OT Chemistry AB develops and manufactures drug dosage forms and inhalation products & devices. The private company is based in Uppsala, Sweden. | Health Technology |
| Synartro AB | |
EpiEndo Pharmaceuticals ehf
 EpiEndo Pharmaceuticals ehf BiotechnologyHealth Technology EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021. | Health Technology |
| OT Pharmaceuticals AB | |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |
